All In Biotech

Drug Trial Radar · NCT06701682

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab

Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients With Acute Respiratory Distress Syndrome (ARDS)

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jun 21, 2025

Primary completion

Jul 2028

Study completion Sep 2028

Sponsor

Lead sponsor
PPD Development, LPIndustry
Sponsor type
Industry
Collaborators
Biomedical Advanced Research and Development Authority; InflaRx GmbH; Edesa Biotech Inc.; Genentech, Inc.
First posted
Nov 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Cohort A: Participants will be randomized to receive either a placebo or vilobelimab. This record describes the default procedures and analyses for Cohort A. Please see NCT06703073 for information on the BP-ARDS-P2-001 Master Protocol.

Conditions

  • Acute Respiratory Distress Syndrome (ARDS)
  • ARDS
  • ARDS (Acute Respiratory Distress Syndrome)
  • Acute Respiratory Distress Syndrome

Interventions

  • Cohort A: vilobelimabDrug

    Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)

  • Cohort A: placeboDrug

    Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortality (ACM) rate at Day 28Time frame: Day 28

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama Hospital

    Birmingham, Alabama · Not yet recruiting

  • Community Regional Medical Center

    Fresno, California · Recruiting

  • Long Beach Memorial Medical Center

    Long Beach, California · Recruiting

  • University of California Irvine Medical Center

    Orange, California · Recruiting

  • University of California Davis Medical Center - Pulmonary Medicine

    Sacramento, California · Recruiting

  • Stanford Medical Center

    Stanford, California · Recruiting

  • Denver Health Hospital and Authority

    Denver, Colorado · Recruiting

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia · Recruiting

  • Nova Clinical Research

    Bradenton, Florida · Recruiting

  • North Florida / South Georgia Veterans Health System

    Gainesville, Florida · Recruiting

  • Sarasota Memorial Hospital

    Sarasota, Florida · Recruiting

  • St. Luke's Boise Medical Center

    Boise, Idaho · Recruiting

  • Northshore University Healthsystem Research Institute

    Evanston, Illinois · Not yet recruiting

  • OSF Saint Francis Medical Center-

    Peoria, Illinois · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Not yet recruiting

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts · Recruiting

  • University of Michigan Hospital

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Health Hospital

    Detroit, Michigan · Recruiting

  • Mayo Clinic

    Rochester, Minnesota · Recruiting

  • Renown Institute for Heart & Vascular Health

    Reno, Nevada · Withdrawn

  • Robert Wood Johnson Medical School

    New Brunswick, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Weill Cornell Medical College

    New York, New York · Not yet recruiting

  • Montefiore Hospital - Moses Campus

    The Bronx, New York · Recruiting

  • Westchester Medical Center

    Valhalla, New York · Not yet recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Durham VA Medical Center

    Durham, North Carolina · Recruiting

  • Duke Lung Transplant Clinic - Clinic 2F/2G - PPDS

    Durham, North Carolina · Not yet recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Not yet recruiting

  • Mercy Health - St. Vincent Medical Center

    Toledo, Ohio · Recruiting

  • The University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina · Recruiting

  • Vanderbilt University Medical Center

    Nashville, Tennessee · Recruiting

  • Baylor All Saints Medical Center

    Fort Worth, Texas · Recruiting

  • Baylor St Luke's Medical Center

    Houston, Texas · Not yet recruiting

  • Houston Methodist Hospital

    Houston, Texas · Not yet recruiting

  • Intermountain Medical Center

    Murray, Utah · Recruiting

  • University of Virginia Health System

    Charlottesville, Virginia · Not yet recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.